Polen Capital's position in Bio-Techne is currently worth $1.43 Million. That's 0.00% of their equity portfolio (95th largest holding). The investor's estimated purchase price is $1.47 Million, resulting in a loss of 2.7%.
Polen Capital, an investment management company, released its “Polen U.S. SMID Company Growth Strategy” fourth-quarter 2023 investor letter. A copy of the sa...
Insider Monkey, 2 months ago… of Bio-Techne Co. (NASDAQ: TECH – Get Rating) by 305.6% … . Analysts Set New Price Targets TECH has been the subject of … 4.04. Bio-Techne (NASDAQ: TECH – ...
EIN News Tech, 11 months agoMINNEAPOLIS, May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial...
PR Newswire, 12 months agohttps://www.investing.com/news/pro/rbc-capital-starts-biotechne-corp-at-sector-perform-432SI-2958575
Investing.com, over 1 year ago